{
  "@context": "aku-v2",
  "@type": "concept",
  "@id": "medicine:vascular:pathology:hit:hit-001",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-05T05:08:00.000Z",
    "contributors": [
      "copilot"
    ],
    "confidence": 0.95,
    "status": "enhanced",
    "board_yield": "HIGH",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/heparin-induced-thrombocytopenia",
    "type": "definition",
    "difficulty": "advanced",
    "importance": "high"
  },
  "content": {
    "title": "Heparin-Induced Thrombocytopenia (HIT)",
    "definition": "Immune-mediated prothrombotic disorder caused by antibodies against heparin-platelet factor 4 (PF4) complexes, resulting in paradoxical thrombocytopenia with high risk of arterial and venous thrombosis. A vascular surgery emergency requiring immediate heparin cessation and alternative anticoagulation.",
    "key_concepts": [
      {
        "term": "Classification",
        "description": "Type I HIT: non-immune, early (1-4 days), mild, self-limited, not dangerous. Type II HIT: immune-mediated, later (5-14 days), antibody-driven, prothrombotic, dangerous"
      },
      {
        "term": "Pathophysiology",
        "description": "Heparin binds PF4 on platelets \u2192 conformational change \u2192 IgG antibodies form against complex \u2192 antibody-bound platelets activate \u2192 platelet aggregation + thrombosis + platelet consumption \u2192 thrombocytopenia"
      },
      {
        "term": "Paradox",
        "description": "Despite low platelets (thrombocytopenia), patients are at HIGH risk of thrombosis (not bleeding). 50% of untreated patients develop thrombosis"
      },
      {
        "term": "Timing",
        "description": "Typical onset 5-14 days after heparin exposure; can occur within 24 hours if prior heparin exposure within 100 days (rapid onset HIT)"
      },
      {
        "term": "4Ts Score",
        "description": "Pre-test probability scoring: Thrombocytopenia (severity/nadir); Timing of platelet fall; Thrombosis (new/progressive); oTher causes excluded. Low (0-3), intermediate (4-5), high (6-8) probability"
      },
      {
        "term": "Thrombocytopenia Pattern",
        "description": "Typically 50% drop from baseline or nadir 20,000-100,000; rarely <20,000 (if so, consider other causes); platelet count alone does not diagnose HIT"
      },
      {
        "term": "Laboratory Testing",
        "description": "Immunoassay (PF4/heparin ELISA) - sensitive but not specific; Serotonin release assay (SRA) - gold standard but slow; 4Ts score guides testing"
      },
      {
        "term": "Treatment",
        "description": "STOP ALL HEPARIN (including flushes, coated catheters); start alternative anticoagulant: argatroban (direct thrombin inhibitor, preferred in renal failure) or bivalirudin or fondaparinux"
      },
      {
        "term": "Warfarin Caution",
        "description": "DO NOT start warfarin until platelets recover >150,000 and on therapeutic alternative anticoagulation; warfarin can cause venous limb gangrene in acute HIT (drops protein C first)"
      },
      {
        "term": "Vascular Surgery Implications",
        "description": "Patients with HIT history need alternative anticoagulation for surgery; bivalirudin for cardiopulmonary bypass; argatroban for vascular procedures; HIT antibodies wane over 3-6 months"
      }
    ],
    "clinical_features": {
      "snomed_codes": [
        "73390007"
      ],
      "icd_10_codes": [
        "D75.82"
      ],
      "symptoms": [
        "New thrombosis symptoms",
        "Often asymptomatic initially"
      ],
      "signs": [
        "Platelet drop 50%+ from baseline",
        "DVT/PE",
        "Arterial thrombosis",
        "Limb ischemia",
        "Skin necrosis at injection sites"
      ],
      "risk_factors": [
        "Unfractionated heparin (UFH > LMWH)",
        "Surgical patients > medical",
        "Female sex",
        "Duration of exposure"
      ]
    },
    "differential_diagnosis": [
      "Sepsis-related thrombocytopenia",
      "DIC",
      "Drug-induced thrombocytopenia",
      "Post-transfusion purpura",
      "ITP",
      "Bone marrow suppression"
    ],
    "statement": "Heparin-Induced Thrombocytopenia (HIT) is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Heparin-Induced-Thrombocytopenia that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Heparin-Induced Thrombocytopenia (HIT) helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Heparin-Induced Thrombocytopenia (HIT) include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Heparin-Induced Thrombocytopenia (HIT)."
    }
  },
  "relationships": {
    "skos:broader": [
      "medicine:hematology:drug-induced-thrombocytopenia"
    ],
    "skos:related": [
      "medicine:vascular:pharmacology:anticoagulation:ac-001",
      "medicine:vascular:pathology:dvt",
      "medicine:hematology:platelet-disorders"
    ],
    "skos:narrower": []
  },
  "pedagogical": {
    "learning_objectives": [
      "Distinguish Type I from Type II HIT",
      "Apply the 4Ts score for pretest probability",
      "Know to STOP all heparin and start alternative anticoagulation",
      "Understand warfarin contraindication in acute HIT"
    ],
    "clinical_pearls": [
      "HIT = thrombocytopenia BUT high thrombosis risk (paradox)",
      "Typical timing: 5-14 days after heparin start",
      "50% drop from baseline is key, not absolute platelet count",
      "4Ts score guides testing - don't test low probability",
      "STOP ALL HEPARIN including flushes and coated lines",
      "NO WARFARIN until platelets >150K (causes limb gangrene)"
    ],
    "common_mistakes": [
      "Not recognizing HIT despite thrombosis + heparin exposure",
      "Starting warfarin in acute HIT (protein C drops first \u2192 gangrene)",
      "Not stopping ALL heparin (including catheter flushes)",
      "Testing low 4Ts probability patients (wastes resources)",
      "Waiting for laboratory confirmation to stop heparin"
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). Heparin-Induced Thrombocytopenia (HIT). Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}